An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo

Journal of Molecular Biology

Volumn 426, Issue 4, 2014, Pages 843-852

  Schiele, Felix ^a   Park, John ^a   Redemann, Norbert ^a   Luippold, Gerd ^a   Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

cynomolgus; Fab; LDL receptor; therapeutic antibody; X ray

Indexed keywords

3H42; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG ACTIVITY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

HEPATITIS C VIRUS; MACACA FASCICULARIS;

APOB; APOLIPOPROTEIN B; C-TERMINAL DOMAIN; CDR; COMPLEMENTARITY-DETERMINING REGION; CTD; CYNOMOLGUS; FAB; LBD; LDL RECEPTOR; LDLR; LIGAND-BINDING DOMAIN; PCSK9; PEG; POLYETHYLENE GLYCOL; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9; SEC; SIZE-EXCLUSION CHROMATOGRAPHY; SPR; SURFACE PLASMON RESONANCE; THERAPEUTIC ANTIBODY; X-RAY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CHO CELLS; CHOLESTEROL, LDL; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MACACA FASCICULARIS; MALE; PROPROTEIN CONVERTASES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SURFACE PLASMON RESONANCE;

EID: 84893692733     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.11.011     Document Type: Article

References (62)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown et al. Heart Disease and Stroke Statistics - 2011 Update 1 Circulation 123 2011 e18 e209
2. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47 (Pubitemid 16037973)
3. H. Jeon, and S.C. Blacklow Structure and physiologic function of the low-density lipoprotein receptor Annu Rev Biochem 74 2005 535 562 (Pubitemid 40995517)
4. C.G. Davis, J.L. Goldstein, T.C. Südhof, R. Anderson, D.W. Russell, and M.S. Brown Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region Nature 326 1986 760 765 (Pubitemid 17057795)
5. M. Varret, M. Abifadel, J.P. Rabès, and C. Boileau Genetic heterogeneity of autosomal dominant hypercholesterolemia Clin Genet 73 2008 1 13 (Pubitemid 350263516)
6. P. Ma, G. Gil, T.C. Südhof, D.W. Bilheimer, J.L. Goldstein, and M.S. Brown Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits Proc Natl Acad Sci 83 1986 8370 8374 (Pubitemid 17182502)
7. N.G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S.B. Jasmin, and S. Stifani et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci 100 2003 928 933 (Pubitemid 36183932)
8. M. Abifadel, M. Varret, J.-P. Rabès, D. Allard, K. Ouguerram, and M. Devillers et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156 (Pubitemid 36666925)
9. S. Benjannet, D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, and W. Jin et al. NARC-1/PCSK9 and its natural mutants zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol J Biol Chem 279 2004 48865 48875 (Pubitemid 39625767)
10. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci USA 101 2004 7100 7105 (Pubitemid 38596449)
11. S.W. Park, Y.-A. Moon, and J.D. Horton Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver J Biol Chem 279 2004 50630 50638 (Pubitemid 39577880)
12. J.C. Cohen, E. Boerwinkle, T.H. Mosley, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
13. A. Zhou, S. Martin, G. Lipkind, J. LaMendola, and D.F. Steiner Regulatory roles of the P domain of the subtilisin-like prohormone convertases J Biol Chem 273 1998 11107 11114 (Pubitemid 28204957)
14. D. Cunningham, D.E. Danley, K.F. Geoghegan, M.C. Griffor, J.L. Hawkins, and T.A. Subashi et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nat Struct Mol Biol 14 2007 413 419 (Pubitemid 46685885)
15. E.N. Hampton, M.W. Knuth, J. Li, J.L. Harris, S.A. Lesley, and G. Spraggon The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain Proc Natl Acad Sci 104 2007 14604 14609 (Pubitemid 350003191)
16. D.E. Piper, S. Jackson, Q. Liu, W.G. Romanow, S. Shetterly, and S.T. Thibault et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol Structure 15 2007 545 552 (Pubitemid 46702689)
17. J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2007 71 77 (Pubitemid 46199197)
18. T.A. Lagace, D.E. Curtis, R. Garuti, M.C. McNutt, S.W. Park, and H.B. Prather et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice J Clin Invest 116 2006 2995 3005 (Pubitemid 44684484)
19. H.J. Kwon, T.A. Lagace, M.C. McNutt, J.D. Horton, and J. Deisenhofer Molecular basis for LDL receptor recognition by PCSK9 Proc Natl Acad Sci 105 2008 1820 1825 (Pubitemid 351439423)
20. D.-W. Zhang, T.A. Lagace, R. Garuti, Z. Zhao, M. McDonald, and J.D. Horton et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 282 2007 18602 18612 (Pubitemid 47100234)
21. P.L. Surdo, M.J. Bottomley, A. Calzetta, E.C. Settembre, A. Cirillo, and S. Pandit et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH EMBO Rep 12 2011 1300 1305
22. G. Rudenko, L. Henry, K. Henderson, K. Ichtchenko, M.S. Brown, and J.L. Goldstein et al. Structure of the LDL receptor extracellular domain at endosomal pH Science 298 2002 2353 2358 (Pubitemid 36014201)
23. M.J. Bottomley, A. Cirillo, L. Orsatti, L. Ruggeri, T.S. Fisher, and J.C. Santoro et al. Structural and biochemical characterization of the wild type PCSK9-EGF (AB) complex and natural familial hypercholesterolemia mutants J Biol Chem 284 2009 1313 1323
24. S. Poirier, G. Mayer, V. Poupon, P.S. McPherson, R. Desjardins, and K. Ly et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation evidence for an intracellular route J Biol Chem 284 2009 28856 28864
25. J.C. Chan, D.E. Piper, Q. Cao, D. Liu, C. King, and W. Wang et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Proc Natl Acad Sci 106 2009 9820 9825
26. H. Liang, J. Chaparro-Riggers, P. Strop, T. Geng, J.E. Sutton, and D. Tsai et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates J Pharmacol Exp Ther 340 2012 228 236
27. Y.G. Ni, J.H. Condra, L. Orsatti, X. Shen, S. Di Marco, and S. Pandit et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake J Biol Chem 285 2010 12882 12891
28. E.A. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, and R. Dufour et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
29. G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N.G. Seidah, and L. Bernier et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 24 2004 1454 1459 (Pubitemid 39050440)
30. B. Dong, M. Wu, H. Li, F.B. Kraemer, K. Adeli, and N.G. Seidah et al. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters J Lipid Res 51 2010 1486 1495
31. P. Bork, L. Holm, and C. Sander The immunoglobulin fold: structural classification, sequence patterns and common core J Mol Biol 242 1994 309 320
32. S. Muyldermans, T. Atarhouch, J. Saldanha, J. Barbosa, and R. Hamers Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains Protein Eng 7 1994 1129 1135 (Pubitemid 24282500)
33. I.I. Ivanov, R.L. Schelonka, Y. Zhuang, G.L. Gartland, M. Zemlin, and H.W. Schroeder Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors J Immunol 174 2005 7773 7780 (Pubitemid 40806284)
34. M. Abifadel, M. Guerin, S. Benjannet, J.-P. Rabès, W. Le Goff, and Z. Julia et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia Atherosclerosis 223 2012 394 400
35. T. Kosenko, M. Golder, G. Leblond, W. Weng, and T.A. Lagace Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation J Biol Chem 288 2013 8279 8288
36. Y.G.L. Saavedra, R. Day, and N.G. Seidah The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway J Biol Chem 287 2012 43492 43501
37. D. Allard, S. Amsellem, M. Abifadel, M. Trillard, M. Devillers, and G. Luc et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia Hum Mutat 26 2005 497-497
38. I.K. Kotowski, A. Pertsemlidis, A. Luke, R.S. Cooper, G.L. Vega, and J.C. Cohen et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol Am J Hum Genet 78 2006 410 422 (Pubitemid 43291224)
39. L. Pisciotta, C.P. Oliva, A.B. Cefalù, D. Noto, A. Bellocchio, and R. Fresa et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia Atherosclerosis 186 2006 433 440
40. G. Mayer, S. Poirier, and N.G. Seidah Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels J Biol Chem 283 2008 31791 31801
41. N.G. Seidah, S. Poirier, M. Denis, R. Parker, B. Miao, and C. Mapelli et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation PLoS One 7 2012 e41865
42. R.M. DeVay, D.L. Shelton, and H. Liang Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2) J Biol Chem 288 2013 10805 10818
43. T. Yamamoto, C. Lu, and R.O. Ryan A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor J Biol Chem 286 2011 5464 5470
44. D.-W. Zhang, R. Garuti, W.-J. Tang, J.C. Cohen, and H.H. Hobbs Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor Proc Natl Acad Sci 105 2008 13045 13050
45. K. Tveten, ∅.L. Holla, J. Cameron, T.B. Strøm, K.E. Berge, and J.K. Laerdahl et al. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification Hum Mol Genet 21 2012 1402 1409
46. D. Sullivan, A.G. Olsson, R. Scott, J.B. Kim, A. Xue, and V. Gebski et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial AMG145 in statin-intolerant patients JAMA J Am Med Assoc 308 2012 2497 2506
47. A. Zaid, A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, and J. Hamelin et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyteâ€specific lowâ€density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 2008 646 654
48. P. Labonté, S. Begley, C. Guévin, M.C. Asselin, N. Nassoury, and G. Mayer et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression Hepatology 50 2009 17 24
49. M.O. Oyewumi, A. Kumar, and Z. Cui Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses Expert Rev Vaccines 9 2010 1095 1107
50. C. Becker, H. Hoschützky, W. Rist, M. Lenter, F.-J. Schneider, and H. Jonuleit Generation of monoclonal antibodies against human regulatory T cells J Immunol Methods 353 2010 62 70
51. J.E. Park, H.H. Chen, J. Winer, K.A. Houck, and N. Ferrara Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J Biol Chem 269 1994 25646 25654
52. D.G. Myszka Improving biosensor analysis J Mol Recognit 12 1999 279 284 (Pubitemid 129708590)
53. R. Karlsson, and A. Fält Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors J Immunol Methods 200 1997 121 133 (Pubitemid 27035694)
54. G.C. Ireton, and B.L. Stoddard Microseed matrix screening to improve crystals of yeast cytosine deaminase Acta Crystallogr Sect D Biol Crystallogr 60 2004 601 605 (Pubitemid 41087611)
55. C. Vonrhein, C. Flensburg, P. Keller, A. Sharff, O. Smart, and W. Paciorek et al. Data processing and analysis with the autoPROC toolbox Acta Crystallogr Sect D Biol Crystallogr 67 2011 293 302
56. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J Appl Crystallogr 40 2007 658 674 (Pubitemid 47080256)
57. E. Potterton, P. Briggs, M. Turkenburg, and E. Dodson A graphical user interface to the CCP4 program suite Acta Crystallogr Sect D Biol Crystallogr 59 2003 1131 1137 (Pubitemid 36872348)
58. M.D. Winn, C.C. Ballard, K.D. Cowtan, E.J. Dodson, P. Emsley, and P.R. Evans et al. Overview of the CCP4 suite and current developments Acta Crystallogr Sect D Biol Crystallogr 67 2011 235 242
59. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr Sect D Biol Crystallogr 60 2004 2126 2132 (Pubitemid 41742764)
60. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, et al. (2008). Global Phasing Ltd. Cambridge, UK, version 2.
61. E. Krissinel, and K. Henrick Inference of macromolecular assemblies from crystalline state J Mol Biol 372 2007 774 797 (Pubitemid 47321791)
62. E. Krissinel, and K. Henrick Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions Acta Crystallogr Sect D Biol Crystallogr 60 2004 2256 2268 (Pubitemid 41742778)